| Name | Title | Contact Details |
|---|
Tenex Health, Inc. (www.tenexhealth.com) (www.tenexhealthpatient.com) develops and markets innovative therapies for the treatment of tendon pain due to trauma or repetitive motion injuries. The minimally invasive technique utilizes the company's proprietary TX MicroTip™ handpiece to cut and debride diseased tissue in an outpatient setting in under 20 minutes, using only a local anesthetic. Since the surrounding healthy tendon tissue is not disturbed, patients enjoy less discomfort and faster recovery times versus traditional open surgical procedures.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
The Centers for Medicare & Medicaid Services (CMS), a federal agency within the U.S. Department of Health and Human Services, is one of the largest purchasers of health care in the world. Medicare, Medicaid, and the Childrens Health Insurance Program (CHIP) provide health care for one in four Americans.
Paradigm Capital Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`re on a mission to make life better for patients taking part in clinical trials around the world, and their caregivers. Our solutions focus on the four key elements of a successful clinical trial: recruitment, engagement, retention and trial outcomes. Combining our in-house technology platforms with 24/7 truly personalised patient care, we focus on creating remarkable patient experiences at every stage of the clinical journey. Remarkable means going above and beyond to support patients in a way that works best for them and their lives. Whether that`s facilitating clinical trial participation in their own homes, supporting them to travel safely to and from study sites, or using technology to manage everything from expense reimbursement to telehealth, we work with our partners to support the protocol design that meets their patient`s needs. Understanding the complexities of the patient journey is paramount to advancing medicine, and exploring digital technology that enables better trial outcomes has never been more important. This all starts with putting patients first in clinical research. When you partner with us, your patients receive a truly remarkable service and your trial outcomes are better.